Literature DB >> 33313965

T1 mapping of the liver and the spleen in patients with liver fibrosis-does normalization to the blood pool increase the predictive value?

Verena Carola Obmann1, Annalisa Berzigotti2, Damiano Catucci1, Lukas Ebner1, Christoph Gräni3, Johannes Thomas Heverhagen1, Andreas Christe1, Adrian Thomas Huber4.   

Abstract

PURPOSE: To analyze whether the T1 relaxation time of the liver is a good predictor of significant liver fibrosis and whether normalization to the blood pool improves the predictive value.
METHODS: This prospective study was conducted between 03/2016 and 02/2018. One hundred seventy-three patients underwent multiparametric liver MRI at 3 T. The T1 relaxation time was measured in the liver and the spleen, in the aorta, the portal vein, and the inferior vena cava (IVC). T1 relaxation times with and without normalization to the blood pool were compared between patients with (n = 26) and without (n = 141) significant liver fibrosis, based on a cutoff value of 3.5 kPa in MRE as the noninvasive reference standard. For statistics, Student's t test, receiver operating characteristic (ROC) curve analysis, and Pearson's correlation were used.
RESULTS: The T1 relaxation time of the liver was significantly longer in patients with liver fibrosis, both with and without blood pool normalization (p < 0.001). T1 relaxation time of the liver allowed prediction of significant liver fibrosis (AUC = 0.88), while normalization to the IVC resulted in a slightly lower performance (AUC = 0.82). The lowest performance was achieved when the T1 relaxation times of the liver were normalized to the aorta (AUC = 0.66) and to the portal vein (AUC = 0.62). The T1 relaxation time of the spleen detected significant liver fibrosis with an AUC of 0.68, and 0.51-0.64 with normalization to the blood pool.
CONCLUSION: The T1 relaxation time of the liver is a good predictor of significant liver fibrosis. However, normalization of the blood pool did not improve the predictive value. KEY POINTS: • The T1 relaxation time of the liver is a good predictor of significant liver fibrosis. • Normalization to the blood pool did not improve the predictive value of T1 mapping. • If the blood pool normalization was weighted 30% to the aorta and 70% to the portal vein, the performance was better than normalization to the aorta alone but still lower than normalization to the IVC.

Entities:  

Keywords:  Cirrhosis; Elasticity imaging techniques; Extracellular space; Liver fibrosis; Magnetic resonance imaging

Mesh:

Year:  2020        PMID: 33313965     DOI: 10.1007/s00330-020-07447-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  1 in total

1.  Computed tomography findings in liver fibrosis and cirrhosis.

Authors:  A Huber; L Ebner; M Montani; N Semmo; K Roy Choudhury; J Heverhagen; A Christe
Journal:  Swiss Med Wkly       Date:  2014-02-19       Impact factor: 2.193

  1 in total
  3 in total

1.  Performance of native and gadoxetate-enhanced liver and spleen T1 mapping for noninvasive diagnosis of clinically significant portal hypertension: preliminary results.

Authors:  Emre Altinmakas; Octavia Bane; Stefanie J Hectors; Rayane Issa; Guillermo Carbonell; Ghadi Abboud; Thomas D Schiano; Swan Thung; Aaron Fischman; Matthew D Kelly; Scott L Friedman; Paul Kennedy; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2022-09-09

2.  Native T1 mapping for differentiating the histopathologic type, grade, and stage of rectal adenocarcinoma: a pilot study.

Authors:  Juan Li; Xuemei Gao; Marcel Dominik Nickel; Jingliang Cheng; Jinxia Zhu
Journal:  Cancer Imaging       Date:  2022-06-17       Impact factor: 5.605

3.  Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.

Authors:  Xiao-He Li; Rui Huang; Ming Yang; Jian Wang; Ying-Hui Gao; Qian Jin; Dan-Li Ma; Lai Wei; Hui-Ying Rao
Journal:  World J Gastroenterol       Date:  2022-05-28       Impact factor: 5.374

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.